Tagged: t-cell-engagers

Sean McCarthy is the chairman, president and CEO of CytomX Therapeutics, a clinical-stage biopharma in South San Francisco building 'Probody' conditionally activated antibodies that switch on inside the tumor and stay quiet everywhere else. An Oxford-trained cancer biologist turned operator, he has run CytomX since 2011, taking it from a venture-backed startup to a Nasdaq-listed company with partnerships across Bristol Myers Squibb, AbbVie, Amgen, Astellas, Moderna and Regeneron.